^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | chiauranib (CS 2164) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor, PDGFR α antagonist, CSF-1R inhibitor, Aurora kinase B inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE Breakthrough Therapy Designation
Published date:
01/05/2021
Excerpt:
Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer (SCLC) with disease progression or recurrence after two lines of prior systematic chemotherapy.
